Description
ACTEMRA ® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. It is manufactured by Roche.
ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor inhibitor indicated for treatment of:
Rheumatoid Arthritis :
Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.